Cenix BioScience Publishes Comprehensive Genome-Wide RNAi Screen of C. elegans
Following the academic pilot, which focused on one of the six chromosomes of C. elegans, the completion of the screen over virtually all ~19,500 genes of the worm genome became the founding project of Cenix BioScience as it started operations in 2000. Led by Dr. Birte Sönnichsen, COO of Cenix and Dr. Echeverri, now CEO/CSO of Cenix, the project yielded new functional insights on over 660 genes, and allowed the identification of several novel human therapeutic targets for the treatment of cancer and other proliferative diseases. The screen has also formed the company's main launching pad towards its present focus of carrying out advanced high throughput, high content applications of RNAi in human and rodent cells to accelerate the development of new therapeutic treatments for a variety of human diseases.
Cenix has enabled free online access to the entire dataset by providing web dissemination rights to one of its parent institutes, the Dresden-based Max Planck Institute for Molecular Cell Biology and Genetics. The full depth of screening data from this landmark study, including approx. 40,000 time lapse recordings, still micrographs and text annotations from over 300,000 microinjection experiments, will thereby become freely accessible and searchable online The dataset has also been made available for cross-referencing through other public online C. elegans databases, including Wormbase.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.